What is the catalog number for 666-15?

The catalog number for 666-15 is HY-101120.

What sizes are available for 666-15?

666-15 is available in the following size(s): 1 mg, 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does 666-15 come in?

666-15 is available in 7 different pack sizes.

666-15 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures 666-15?

666-15 is manufactured by QuantiMol.

What is the estimated delivery time for 666-15?

Estimated delivery time for 666-15 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for 666-15?

The safety data sheet for 666-15 is available here: http://file.medchemexpress.com/batch_PDF/HY-101120/666-15-SDS-MedChemExpress.pdf.

666-15

666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model[1][2].

Product Specifications

CAS Number

1433286-70-4

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/666-15.html

Purity

99.79

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(Cl)C=C1O)C2=CC3=CC=CC=C3C=C2OCCNC(C4=C(OCCCN)C=C(C=CC=C5)C5=C4)=O.Cl

Molecular Formula

C33H31Cl2N3O5

Molecular Weight

620.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Xie F, et al. Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity. J Med Chem. 2015 Jun 25;58 (12) :5075-87.|[2]Zhang B, et al. C1q-TNF-related protein-3 attenuates pressure overload-induced cardiac hypertrophy by suppressing the p38/CREB pathway and p38-induced ER stress. Cell Death Dis. 2019 Jul 8;10 (7) :520.|[3]Qin Y, et al. Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. Sci Adv. 2020 Feb 19;6 (8) :eaaw9960.